AAAAAA

   
Results: 1-15 |
Results: 15
Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients
Authors: Pierga, JY Robain, M Jouve, M Asselain, B Dieras, V Beuzeboc, P Palangie, T Dorval, T Extra, JM Scholl, S Pouillart, P
Citation: Jy. Pierga et al., Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients, ANN ONCOL, 12(2), 2001, pp. 231-237
Targeting HER2 in other tumor types
Authors: Scholl, S Beuzeboc, P Pouillart, P
Citation: S. Scholl et al., Targeting HER2 in other tumor types, ANN ONCOL, 12, 2001, pp. 81-87
Interaction between Herceptin((R)) and taxanes
Authors: Dieras, V Beuzeboc, P Laurence, V Pierga, JY Pouillart, P
Citation: V. Dieras et al., Interaction between Herceptin((R)) and taxanes, ONCOL-BASEL, 61, 2001, pp. 43-49
Germ cell tumors in patients infected by the human immunodeficiency virus
Authors: Fizazi, K Amato, RJ Beuzeboc, P Petit, N Bouhour, D Thiss, A Rebischung, C Chevreau, C Logothetis, CJ Droz, JP
Citation: K. Fizazi et al., Germ cell tumors in patients infected by the human immunodeficiency virus, CANCER, 92(6), 2001, pp. 1460-1467
Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy
Authors: Pierga, JY Asselain, B Jouve, M Dieras, V Carton, M Laurence, V Girre, V Beuzeboc, P Palangie, T Dorval, T Pouillart, P
Citation: Jy. Pierga et al., Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy, CANCER, 91(6), 2001, pp. 1079-1089
Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases
Authors: Tubiana-Hulin, M Beuzeboc, P Mauriac, L Barbet, N Frenay, M Monnier, A Pion, JM Switsers, O Misset, JL Assadourian, S Bessa, E
Citation: M. Tubiana-hulin et al., Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases, B CANCER, 88(7), 2001, pp. 701-707
Intraabdominal desmoplastic small round cell tumor - Report of a case withfine needle aspiration, cytologic diagnosis and molecular confirmation
Authors: Ferlicot, S Coue, O Gilbert, E Beuzeboc, P Servois, V Klijanienko, J Delattre, O Vielh, P
Citation: S. Ferlicot et al., Intraabdominal desmoplastic small round cell tumor - Report of a case withfine needle aspiration, cytologic diagnosis and molecular confirmation, ACT CYTOL, 45(4), 2001, pp. 617-621
ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy
Authors: Vincent-Salomon, A Carton, M Freneaux, P Palangie, T Beuzeboc, P Mouret, E de Cremoux, P Coue, O Zafrani, B Nicolas, A Clough, K Fourquet, A Pouillart, P Sastre-Garau, X
Citation: A. Vincent-salomon et al., ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy, EUR J CANC, 36(5), 2000, pp. 586-591
Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer
Authors: Robain, M Pierga, JY Jouve, M Asselain, B Dieras, V Beuzeboc, P Palangie, T Dorval, T Extra, JM Scholl, S Pouillart, P
Citation: M. Robain et al., Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer, EUR J CANC, 36(18), 2000, pp. 2301-2312
Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma
Authors: Couturier, J Vincent-Salomon, A Nicolas, A Beuzeboc, P Mouret, E Zafrani, B Sastre-Garau, X
Citation: J. Couturier et al., Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma, MOD PATHOL, 13(11), 2000, pp. 1238-1243
Budgeting novel anti-cancer drugs: with which resources?
Authors: Livartowski, A Beuzeboc, P Le Vu, B Courbard, M Pierga, JY Extra, JM Scholl, S Pouillart, P
Citation: A. Livartowski et al., Budgeting novel anti-cancer drugs: with which resources?, B CANCER, 87(10), 2000, pp. 745-754
Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer
Authors: Pierga, JY Mouret, E Dieras, V Laurence, V Beuzeboc, P Dorval, T Palangie, T Jouve, M Vincent-Salomon, A Scholl, S Extra, JM Asselain, B Pouillart, P
Citation: Jy. Pierga et al., Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer, BR J CANC, 83(11), 2000, pp. 1480-1487
Neoadjuvant chemotherapy in young breast cancer patients: Correlation between response and relapse?
Authors: Braud, AC Asselain, B Scholl, S De la Rochefordiere, A Palangie, T Dieras, V Pierga, JY Dorval, T Jouve, M Beuzeboc, P Pouillart, P
Citation: Ac. Braud et al., Neoadjuvant chemotherapy in young breast cancer patients: Correlation between response and relapse?, EUR J CANC, 35(3), 1999, pp. 392-397
Dose-finding study of docetaxel and doxorubicin in first-line treatment ofpatients with metastatic breast cancer
Authors: Misset, JL Dieras, V Gruia, G Bourgeois, H Cvitkovic, E Kalla, S Bozec, L Beuzeboc, P Jasmin, C Aussel, JP Riva, A Azli, N Pouillart, P
Citation: Jl. Misset et al., Dose-finding study of docetaxel and doxorubicin in first-line treatment ofpatients with metastatic breast cancer, ANN ONCOL, 10(5), 1999, pp. 553-560
Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene
Authors: Beuzeboc, P Scholl, S Garau, XS Vincent-Salomon, A de Cremoux, P Couturier, J Palangie, T Pouillard, P
Citation: P. Beuzeboc et al., Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene, B CANCER, 86(6), 1999, pp. 544-548
Risultati: 1-15 |